該当箇所へ

Unlocking High-Throughput Mass Spectrometry with Digital Ecosystems

January 19, 2026
Raed Hmadi

A single digital ecosystem for HT-MS, from raw MS data to actionable, biological insights, all integrated within a central data backbone, suitable for deployments in regulated environments — enhanced by AI-powered analytics.

Building a Digital Ecosystem for High-Throughput Drug Discovery 

A modern digital ecosystem for HT-MS relies on four core components: standardized data capture, automated processing, advanced visualization, and AI-driven analytics7,9. A platform such as the Genedata Biopharma Platform unifies these elements into an end-to-end environment that orchestrates HT-MS workflows at scale.

This ecosystem integrates liquid handling automation, next-generation MS platforms, and advanced software, allowing large volumes of heterogeneous data to flow seamlessly from acquisition to analysis6,7. It captures detailed metadata, including experimental conditions, instrument parameters, and sample lineage, to support compliance, reproducibility, and multi-site standardization. This infrastructure accelerates decision-making by enabling earlier triage of unsuitable compounds5,6.

Automated workflows connect acquisition directly to analysis using approaches such as compressed data snapshots, which reduce file size while preserving diagnostic information10. Interactive spectral visualization tools allow scientists to explore complex datasets within the same environment, moving efficiently from raw spectra to decision-ready results1.

Cloud-Native Solutions: Scaling MS Workflows Globally

Enterprise cloud platforms are essential for scaling HT-MS operations, offering capabilities that on-premises infrastructure cannot match. Cloud-native solutions provide on-demand compute capacity so laboratories can process peak data loads in real time without investing in permanent, high-cost hardware. This scalability also breaks down data silos by giving global teams unified access to shared datasets, supporting seamless collaboration across R&D centers.

The efficiency gains are substantial. For example, analyzing samples with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) completes analysis in approximately six hours, compared with more than three days using conventional LC-MS/MS11. Furthermore, AEMS has demonstrated an up to 60-fold faster turnaround (5 minutes vs. 5 hours)12. These examples highlight the scale of acceleration possible when high-throughput instrumentation is paired with flexible, scalable compute.

Beyond speed, cloud platforms support regulatory compliance through secure, immutable audit trails and centralized data governance. When combined with a platform like the Genedata Biopharma Platform, cloud-native architectures standardize HT-MS workflows, enforce data policies, and deliver consistent access to validated analysis pipelines across global operations.

AI and ML Applications in HT-MS

ML methods are increasingly used in HT-MS workflows for automated raw data processing, including peak picking, peak integration, and peak classification through approaches such as convolutional neural networks (CNNs)8,13. Tools such as UniDec support deconvolution of complex mass spectra14.

AI improves data fidelity by modeling nonlinear relationships in large, heterogeneous datasets — relationships that traditional processing methods often fail to capture5,6,9,13. Once HT-MS data is standardized and centrally accessible, AI and ML can detect subtle patterns, assay drift, and batch effects that manual review might overlook, strengthening data-driven decision-making.

High-quality data is essential for successful AI outcomes, as model performance directly depends on data quality. A digital ecosystem ensures that HT-MS data is curated, standardized, and traceable: prerequisites for training reliable ML models capable of predicting compound behavior and optimizing screening campaigns10. Significant effort is also required to standardize mass spectra for database sharing and to develop benchmark datasets for comparing ML methods across studies5,9,13.

Future Outlook: Transforming Drug Discovery with HT-MS and Digital Ecosystems 

The convergence of HT-MS platforms with powerful computational infrastructure is redefining next-generation drug discovery. Together, they enable direct, label-free analysis at scale while ensuring robust data management for emerging target classes5,11. 

HT-MS will also increasingly integrate with other high-dimensional technologies to provide a more holistic understanding of drug response. Pairing HT-MS with phenotypic cellular assays enables multi-omics workflows that incorporate genomic, proteomic, and metabolomic data to reveal mechanisms of action (MoA). High content screening (HCS) enriches this further by combining imaging with MS for multiparametric readouts5,6,9,13.

Investing in digital ecosystems is now strategically essential for reducing development costs and timelines. Significant reductions in assay costs and analysis time can accelerate decision-making and have been estimated to yield savings of up to $130 million and nearly a year during new drug development5,6. While actual impact varies by portfolio, the trend is clear: drug discovery is becoming increasingly data-centric, automated, and globally scalable.

As high-throughput assays continue to evolve, data intelligence extracted through computational tools will drive faster, more-informed decisions and support continuous learning across the R&D pipeline6,13. Organizations investing in integrated digital platforms such as the Genedata Biopharma Platform will be well positioned to lead the next wave of innovation in drug discovery.

 

This blog is adapted from an article that originally appeared on LCGC.

 

 

FAQs

High-throughput screening (HTS) is a method that uses automation and advanced detection technologies to rapidly evaluate large numbers of compounds at scale. It enables large-scale evaluation of chemical matter and supports a range of assay formats, including modern label-free approaches such as high-throughput mass spectrometry (HT-MS) as well as traditional optical and fluorescence-based assays.

High-throughput screening (HTS) accelerates early discovery by screening large compound libraries against selected targets to identify active chemical matter. It is considered a key methodology for hit finding and early triage, enabling researchers to quickly assess which compounds bind to or modulate a therapeutic target. As high-throughput mass spectrometry (HT-MS) becomes more widely integrated as a label-free readout, HTS benefits from improved data quality and greater confidence during hit confirmation.

High-throughput mass spectrometry (HT-MS) applies modern mass spectrometry (MS) instrumentation and automation to enable rapid, label-free analysis at large scale. MS measures mass-to-charge (m/z) ratios with high sensitivity and specificity, and HT-MS is generally less susceptible to assay interferences than optical methods, making it suitable for robust hit identification.

High-throughput analysis (HTA) refers to methods that use automation and robotics to evaluate large numbers of samples or compounds rapidly. Standard high-throughput screening (HTS) campaigns evaluate approximately 10,000 to 100,000 compounds per day. Ultra-high-throughput screening (uHTS) extends this capacity to hundreds of thousands or even millions of assays per campaign, depending on assay design and instrumentation.

References

  1. Natali, E.; Hersch, J.; Freiberg, C.; Steigele, S. Advancing Large-Molecule Discovery with a Unified Digital Platform for Data Analysis and Workflow Management. mAbs2025, 17 (1), 2555346. https://doi.org/10.1080/19420862.2025.2555346.
  2. Van Puyvelde, B.; Hunter, C. L.; Zhgamadze, M.; Savant, S.; Wang, Y. O.; Hoedt, E.; Raedschelders, K.; Pope, M.; Huynh, C. A.; Ramanujan, V. K.; Tourtellotte, W.; Razavi, M.; Anderson, N. L.; Martens, G.; Deforce, D.; Fu, Q.; Dhaenens, M.; Van Eyk, J. E. Acoustic Ejection Mass Spectrometry Empowers Ultra-Fast Protein Biomarker Quantification. Nat. Commun.2024, 15 (1), 5114. https://doi.org/10.1038/s41467-024-48563-z.
  3. Dueñas, M. E.; Peltier‐Heap, R. E.; Leveridge, M.; Annan, R. S.; Büttner, F. H.; Trost, M. Advances in High‐throughput Mass Spectrometry in Drug Discovery. EMBO Mol. Med.2023, 15 (1), e14850. https://doi.org/10.15252/emmm.202114850.
  4. Van Puyvelde, B.; Hunter, C. L.; Zhgamadze, M.; Savant, S.; Wang, Y. O.; Hoedt, E.; Raedschelders, K.; Pope, M.; Huynh, C. A.; Ramanujan, V. K.; Tourtellotte, W.; Razavi, M.; Anderson, N. L.; Martens, G.; Deforce, D.; Fu, Q.; Dhaenens, M.; Van Eyk, J. E. Acoustic Ejection Mass Spectrometry Empowers Ultra-Fast Protein Biomarker Quantification. Nat. Commun.2024, 15 (1), 5114. https://doi.org/10.1038/s41467-024-48563-z.
  5. Dueñas, M. E.; Peltier‐Heap, R. E.; Leveridge, M.; Annan, R. S.; Büttner, F. H.; Trost, M. Advances in High‐throughput Mass Spectrometry in Drug Discovery. EMBO Mol. Med.2023, 15 (1), e14850. https://doi.org/10.15252/emmm.202114850.
  6. Szymański, P.; Markowicz, M.; Mikiciuk-Olasik, E. Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests. Int. J. Mol. Sci.2011, 13 (1), 427–452. https://doi.org/10.3390/ijms13010427.
  7. Liebal, U. W.; Phan, A. N. T.; Sudhakar, M.; Raman, K.; Blank, L. M. Machine Learning Applications for Mass Spectrometry-Based Metabolomics. Metabolites2020, 10 (6), 243. https://doi.org/10.3390/metabo10060243.
  8. Melnikov, A. D.; Tsentalovich, Y. P.; Yanshole, V. V. Deep Learning for the Precise Peak Detection in High-Resolution LC–MS Data. Anal. Chem.2020, 92 (1), 588–592. https://doi.org/10.1021/acs.analchem.9b04811.
  9. Beck, A. G.; Muhoberac, M.; Randolph, C. E.; Beveridge, C. H.; Wijewardhane, P. R.; Kenttämaa, H. I.; Chopra, G. Recent Developments in Machine Learning for Mass Spectrometry. ACS Meas. Sci. Au2024, 4 (3), 233–246. https://doi.org/10.1021/acsmeasuresciau.3c00060.
  10. Radziński, P.; Skrajny, J.; Moczulski, M.; Ciach, M. A.; Valkenborg, D.; Balluff, B.; Gambin, A. Efficient Compression of Mass Spectrometry Images via Contrastive Learning-Based Encoding. Anal. Chem.2025, 97 (29), 15579–15585. https://doi.org/10.1021/acs.analchem.4c06913.
  11. McLaren, D. G.; Shah, V.; Wisniewski, T.; Ghislain, L.; Liu, C.; Zhang, H.; Saldanha, S. A. High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives. SLAS Discov.2021, 26 (2), 168–191. https://doi.org/10.1177/2472555220980696.
  12. Zhang, H.; Liu, C.; Hua, W.; Ghislain, L. P.; Liu, J.; Aschenbrenner, L.; Noell, S.; Dirico, K. J.; Lanyon, L. F.; Steppan, C. M.; West, M.; Arnold, D. W.; Covey, T. R.; Datwani, S. S.; Troutman, M. D. Acoustic Ejection Mass Spectrometry for High-Throughput Analysis. Anal. Chem.2021, 93 (31), 10850–10861. https://doi.org/10.1021/acs.analchem.1c01137.
  13. Liebal, U. W.; Phan, A. N. T.; Sudhakar, M.; Raman, K.; Blank, L. M. Machine Learning Applications for Mass Spectrometry-Based Metabolomics. Metabolites2020, 10 (6), 243. https://doi.org/10.3390/metabo10060243.
  14. Mojumdar, A.; Yoo, H.-J.; Kim, D.-H.; Park, J.; Park, S.-J.; Jeon, E.; Choi, S.; Choi, J. H.; Park, M.; Bang, G.; Cho, K. Advances in Mass Spectrometry-Based Approaches for Characterizing Monoclonal Antibodies: Resolving Structural Complexity and Analytical Challenges. J. Anal. Sci. Technol.2024, 15 (1), 23. https://doi.org/10.1186/s40543-024-00437-1.